CN103110655A - 马齿苋生物碱单体化合物在制备抗肿瘤药物中的应用 - Google Patents
马齿苋生物碱单体化合物在制备抗肿瘤药物中的应用 Download PDFInfo
- Publication number
- CN103110655A CN103110655A CN2013100567239A CN201310056723A CN103110655A CN 103110655 A CN103110655 A CN 103110655A CN 2013100567239 A CN2013100567239 A CN 2013100567239A CN 201310056723 A CN201310056723 A CN 201310056723A CN 103110655 A CN103110655 A CN 103110655A
- Authority
- CN
- China
- Prior art keywords
- purslane
- alkaloid
- preparation
- application
- oleracein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 20
- 229930013930 alkaloid Natural products 0.000 title claims abstract description 18
- 150000003797 alkaloid derivatives Chemical class 0.000 title claims abstract description 18
- 238000002360 preparation method Methods 0.000 title claims abstract description 12
- 239000003814 drug Substances 0.000 title abstract description 15
- 230000000259 anti-tumor effect Effects 0.000 title abstract description 6
- 235000001855 Portulaca oleracea Nutrition 0.000 title abstract 5
- 241000219304 Portulacaceae Species 0.000 title abstract 5
- VZPAURMDJZOGHU-UHFFFAOYSA-N N-benzoyl-L-phenylalanyl-L-phenylalaniol acetate Natural products C=1C=CC=CC=1CC(NC(=O)C=1C=CC=CC=1)C(=O)NC(COC(=O)C)CC1=CC=CC=C1 VZPAURMDJZOGHU-UHFFFAOYSA-N 0.000 claims abstract description 19
- 108010080154 N-benzoylphenylalanylphenylalinol acetate Proteins 0.000 claims abstract description 19
- VZPAURMDJZOGHU-DQEYMECFSA-N [(2s)-2-[[(2s)-2-benzamido-3-phenylpropanoyl]amino]-3-phenylpropyl] acetate Chemical compound C([C@@H](COC(=O)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)C=1C=CC=CC=1)C1=CC=CC=C1 VZPAURMDJZOGHU-DQEYMECFSA-N 0.000 claims abstract description 19
- GQZLXTLYIXYZIJ-ZEQRLZLVSA-N aurantiamide acetate Natural products CC(=O)OC[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)c2ccccc2)c3ccccc3 GQZLXTLYIXYZIJ-ZEQRLZLVSA-N 0.000 claims abstract description 19
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 claims abstract description 5
- 208000032839 leukemia Diseases 0.000 claims abstract description 5
- 201000005249 lung adenocarcinoma Diseases 0.000 claims abstract description 5
- HTRBZHHBMJDWGG-CGHSGWKJSA-N (2S)-5-hydroxy-1-[(E)-3-(4-hydroxy-3-methoxyphenyl)prop-2-enoyl]-6-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-2,3-dihydroindole-2-carboxylic acid Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)N2C3=CC(O[C@H]4[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O4)O)=C(O)C=C3C[C@H]2C(O)=O)=C1 HTRBZHHBMJDWGG-CGHSGWKJSA-N 0.000 claims description 17
- HTRBZHHBMJDWGG-UHFFFAOYSA-N oleracein B Natural products C1=C(O)C(OC)=CC(C=CC(=O)N2C3=CC(OC4C(C(O)C(O)C(CO)O4)O)=C(O)C=C3CC2C(O)=O)=C1 HTRBZHHBMJDWGG-UHFFFAOYSA-N 0.000 claims description 17
- 239000000178 monomer Substances 0.000 claims description 14
- 239000002246 antineoplastic agent Substances 0.000 claims description 10
- 229940041181 antineoplastic drug Drugs 0.000 claims description 10
- 230000005764 inhibitory process Effects 0.000 claims description 5
- 230000012010 growth Effects 0.000 claims description 3
- 150000001408 amides Chemical class 0.000 abstract 2
- OAVCWZUKQIEFGG-UHFFFAOYSA-O 2-(5-methyl-2H-tetrazol-1-ium-1-yl)-1,3-thiazole Chemical compound CC1=NN=N[NH+]1C1=NC=CS1 OAVCWZUKQIEFGG-UHFFFAOYSA-O 0.000 abstract 1
- 230000009036 growth inhibition Effects 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 14
- 206010028980 Neoplasm Diseases 0.000 description 9
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- 201000011510 cancer Diseases 0.000 description 6
- 229940079593 drug Drugs 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 238000004113 cell culture Methods 0.000 description 4
- 0 CC1*(CC=C=CC)(*[C@](C(*)N)*=*C)C1 Chemical compound CC1*(CC=C=CC)(*[C@](C(*)N)*=*C)C1 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 230000001093 anti-cancer Effects 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 239000012531 culture fluid Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 230000001629 suppression Effects 0.000 description 3
- NWXMGUDVXFXRIG-WESIUVDSSA-N (4s,4as,5as,6s,12ar)-4-(dimethylamino)-1,6,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4,4a,5,5a-tetrahydrotetracene-2-carboxamide Chemical compound C1=CC=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]4(O)C(=O)C3=C(O)C2=C1O NWXMGUDVXFXRIG-WESIUVDSSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 229930195573 Amycin Natural products 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 241000219295 Portulaca Species 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 238000011275 oncology therapy Methods 0.000 description 2
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- 238000005084 2D-nuclear magnetic resonance Methods 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- SLMMZNONABTNIB-DNQXCXABSA-N Aurantiamide Natural products OC[C@@H](Cc1ccccc1)NC(=O)[C@@H](CC(=O)c2ccccc2)Cc3ccccc3 SLMMZNONABTNIB-DNQXCXABSA-N 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- KSVKECXWDNCRTM-UHFFFAOYSA-N Deacetyl-asperglaucid Natural products C=1C=CC=CC=1CC(NC(=O)C=1C=CC=CC=1)C(=O)NC(CO)CC1=CC=CC=C1 KSVKECXWDNCRTM-UHFFFAOYSA-N 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 201000000297 Erysipelas Diseases 0.000 description 1
- 206010054787 Haemorrhoidal haemorrhage Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 241001299553 Ilex chinensis Species 0.000 description 1
- 241001100935 Ilex purpurea Species 0.000 description 1
- 235000003366 Ilex purpurea Nutrition 0.000 description 1
- 208000006877 Insect Bites and Stings Diseases 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
- 208000004078 Snake Bites Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 229930182482 anthraquinone glycoside Natural products 0.000 description 1
- 229940098421 anthraquinone glycoside Drugs 0.000 description 1
- 150000008139 anthraquinone glycosides Chemical class 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 108010025480 aurantiamide Proteins 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 201000008275 breast carcinoma Diseases 0.000 description 1
- 229940097217 cardiac glycoside Drugs 0.000 description 1
- 239000002368 cardiac glycoside Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000003255 drug test Methods 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 235000019441 ethanol Nutrition 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 208000035861 hematochezia Diseases 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000012567 medical material Substances 0.000 description 1
- XELZGAJCZANUQH-UHFFFAOYSA-N methyl 1-acetylthieno[3,2-c]pyrazole-5-carboxylate Chemical compound CC(=O)N1N=CC2=C1C=C(C(=O)OC)S2 XELZGAJCZANUQH-UHFFFAOYSA-N 0.000 description 1
- KSVKECXWDNCRTM-GOTSBHOMSA-N n-[(2s)-1-[[(2s)-1-hydroxy-3-phenylpropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]benzamide Chemical compound C([C@@H](CO)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)C=1C=CC=CC=1)C1=CC=CC=C1 KSVKECXWDNCRTM-GOTSBHOMSA-N 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- LPMXVESGRSUGHW-HBYQJFLCSA-N ouabain Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@@H]1C[C@@]2(O)CC[C@H]3[C@@]4(O)CC[C@H](C=5COC(=O)C=5)[C@@]4(C)C[C@@H](O)[C@@H]3[C@@]2(CO)[C@H](O)C1 LPMXVESGRSUGHW-HBYQJFLCSA-N 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 229930002534 steroid glycoside Natural products 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 238000003805 vibration mixing Methods 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明公布了两种马齿苋生物碱单体化合物在制备抗肿瘤药物中的应用,其中所述马齿苋生物碱单体化合物是指马齿苋酰胺B及橙黄胡椒酰胺。采用MTT[3-(4,5)-双甲基-2-噻唑-(2,5)-苯基溴化四氮唑蓝]法测定两种单体化合物对人肺腺癌细胞(A549)、人白血病细胞株(K562)的抑制活性。结果表明,两种单体化合物均具有显著的抑制生长作用,因此说明马齿苋酰胺B、橙黄胡椒酰胺两种单体化合物可以在制备抗肿瘤药物中应用。
Description
技术领域
本发明涉及一种马齿苋生物碱单体化合物在制备抗肿瘤药物中的应用,属医药领域。
背景技术
癌症是危害人类健康的大敌。我国每年新发癌症病例约有160万人,每年死于癌症的约有130万人,全国因癌症而死亡的人数逐年上升,我国为肺癌、乳腺癌、肝癌等癌症的高发区域,癌症死亡率去居高不下。
在过去的半个世纪中,大量的科研力量致力于抗肿瘤药物的研究,同时也有一些有效的药物上市造福肿瘤患者,但是仍有许多急待解决的问题,如对肿瘤细胞的选择性抑制较差,一些抗肿瘤药物在治疗患者所患癌症的同时却引发新的肿瘤的形成。所以,目前寻找具有更高选择性、更低毒性的抗癌药物仍是研究的热点,所以本发明研究马齿苋生物碱单体化合物抗肿瘤活性旨在找出具有更好抗癌活性的新型药物。
马齿苋(portulaca oleracea L.)为马齿苋科马齿苋属植物,分布于全国各地,以及世界范围内的温带、亚热带、热带地区。资源丰富,来源广泛,无毒副作用。多以其干燥地上部分入药,性味酸、寒,具有清热解毒、凉血止血、止痢的功效,用于热毒血痢、湿疹、丹毒、蛇虫咬伤、便血、痔血和崩漏下血。近年来,国内外学者研究发现,马齿苋对人体具有多种药理作用,如抗癌、杀菌、降血脂、降血糖、抗动脉粥样硬化等。这些功效与其含有生物碱、去甲基肾上腺素、多糖、不饱和脂肪酸、黄酮类、强心苷和蒽醌苷等生物活性成分有关。
前期工作中,本课题组在马齿苋生物碱提取物中分离得到马齿苋酰胺B及橙黄胡椒酰胺,其中橙黄胡椒酰胺是首次在马齿苋植物中分离得到的单体化合物。其结构如下,但是到目前为止,这两种单体化合物的抗肿瘤活性及其作为抗癌药物的应用还未见文献报道。
马齿苋酰胺B(Oleracein B) 橙黄胡椒酰胺(aurantiamide)。
发明内容
本发明提供一种马齿苋生物碱单体化合物在制备抗肿瘤药物中的应用,旨在寻找具有更好抗癌活性的新型药物。
本发明是通过以下技术方案来实现的:
马齿苋生物碱单体化合物在制备抗肿瘤药物中的应用,其特征在于:马齿苋生物碱单体化合物是指马齿苋酰胺B、橙黄胡椒酰胺两种单体,其分子结构式分别为:
马齿苋酰胺B 橙黄胡椒酰胺
如上所述的马齿苋生物碱单体化合物在制备抗肿瘤药物中的应用,其特征在于:马齿苋酰胺B、橙黄胡椒酰胺两种单体对人肺腺癌细胞、人白血病细胞株均具有显著的抑制生长作用。
优点及效果:本发明采用MTT法测定从马齿苋中分离得到的马齿苋酰胺B及橙黄胡椒酰胺对人肺腺癌细胞(A549)、人白血病细胞株(K562)的抑制活性,结果表明两种单体化合物均具有显著的抑制生长作用,因此可以用于制备抗肿瘤的药物。本发明发掘了马齿苋酰胺B及橙黄胡椒酰胺新的药用前景,开拓了一个新的药用领域。
实施方式:
本发明通过以下实施例进一步详细说明本发明。
实施例1:马齿苋酰胺B及橙黄胡椒酰胺的提取分离及结构鉴定。
购买马齿苋药材(约100 kg),用无水乙醇搅拌提取3次,每次1小时,回收乙醇,得黑色浸膏。在浸膏中加入10%硫酸溶解,过滤。用氨水调pH至10.0,加入饱和NaCl 水溶液。二氯甲烷萃取,得二氯甲烷层,挥干得富含生物碱提取物浸膏。生物碱提取物浸膏经过反复硅胶色谱、Sephadex LH-20、ODS及制备液相等分离手段,结合理化性质和现代波谱学手段(UV、IR、MS、1H-NMR、13C-NMR和2D-NMR)从中分离鉴定出两个单体化合物,分别是马齿苋酰胺B及橙黄胡椒酰胺。
实施例2:马齿苋酰胺B及橙黄胡椒酰胺体外抗肿瘤活性研究。
采用MTT法测定马齿苋酰胺B及橙黄胡椒酰胺对人肺腺癌细胞(A549)、人白血病细胞株(K562)的抑制活性。
(1)仪器与试剂:RPMI 1640培养液、DMEM培养基购自Hyclone公司,胎牛血清为杭州四季青产品;CKX31型倒置显微镜(菲律宾奥林巴斯公司);恒温CO2培养箱(美国Thermo公司);5810 R型台式高速低温离心机(德国Eppendorf公司);全自动酶标仪(美国Biotek集团)。
(2)细胞培养:A549细胞培养于DMEM培养基(含10%胎牛血清),K562培养于1640培养基(含10%胎牛血清),37℃、含5% CO2湿化恒温孵箱中培养。每2-3天传代一次。实验时取对数生长期细胞,0.4%台盼蓝鉴定细胞活性在98%以上。
(3)MTT法测定细胞活性:取对数生长期的A549、K562细胞,调整密度至1×105/mL,接种于96孔板,100μL/孔,A549细胞培养12h后,K562细胞培养1h后,第一组,加入不同浓度的橙黄胡椒酰胺至终浓度分别为11.69、23.3、46.75、93.5、187、374μmol/L。第二组,加入不同浓度的马齿苋酰胺B至终浓度分别为8.79、17.5、35.17、70.3、140.7、281μmol/L。两组每个浓度设3个复孔,实验分为药物试验组(分别加入不同浓度的测试药)、阴性对照组(只加培养液和细胞,不加测试药),阳性对照组(加培养液和细胞,并加入阿霉素作为阳性对照药),调零组(只加培养液,不加细胞和测试药)。在37℃、5% CO2孵箱培养24h,每孔加5g/L的MTT 20μL继续孵育4h,去上清液,然后每孔加入150μL DMSO振荡混匀15 min,用酶标仪测定A490nm值,以A490 nm间接反映存活细胞数量。据此可推测各浓度生物碱对细胞的抑制率。抑制率=(A 对照组-A 加药组)/A 对照组×100%。各组实验均重复3次,实验数据用spass17.0统计分析。以阿霉素作为阳性对照。
测得的抑制率见表1所示:
表1
注: * p < 0.01 vs control,**p < 0.001 vs control.
结果表明:马齿苋酰胺B及橙黄胡椒酰胺均具有较好的抑制肿瘤生长活性,且在测定剂量范围内呈剂量依赖关系。
Claims (2)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310056723.9A CN103110655B (zh) | 2013-02-22 | 2013-02-22 | 马齿苋生物碱单体化合物在制备抗肿瘤药物中的应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310056723.9A CN103110655B (zh) | 2013-02-22 | 2013-02-22 | 马齿苋生物碱单体化合物在制备抗肿瘤药物中的应用 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201410105531.7A Division CN103830214A (zh) | 2013-02-22 | 2013-02-22 | 马齿苋生物碱单体化合物在制备抗肿瘤药物中的应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103110655A true CN103110655A (zh) | 2013-05-22 |
CN103110655B CN103110655B (zh) | 2015-03-25 |
Family
ID=48409056
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201310056723.9A Active CN103110655B (zh) | 2013-02-22 | 2013-02-22 | 马齿苋生物碱单体化合物在制备抗肿瘤药物中的应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN103110655B (zh) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105085534A (zh) * | 2014-12-22 | 2015-11-25 | 辽宁中医药大学 | 一种新骨架生物碱化合物及其提取分离方法 |
CN111494567A (zh) * | 2020-05-27 | 2020-08-07 | 巧济堂(山东)药业有限公司 | 一种中药组合物及其制备方法、口服药剂、应用 |
CN114805175A (zh) * | 2022-05-24 | 2022-07-29 | 辽宁大学 | 马齿苋中新的化合物及其衍生物及其在治疗糖尿病药物中的应用 |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104592798B (zh) * | 2014-12-29 | 2017-06-09 | 岭南师范学院 | 乙酸橙酰胺在海洋污损生物防除中的应用 |
CN106008502B (zh) * | 2016-06-06 | 2017-09-26 | 辽宁中医药大学 | 马齿苋中骨架生物碱化合物及其提取分离方法 |
-
2013
- 2013-02-22 CN CN201310056723.9A patent/CN103110655B/zh active Active
Non-Patent Citations (1)
Title |
---|
解思友等: "《马齿苋的化学成分与药理作用最新研究进展》", 《现代药物与临床》 * |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105085534A (zh) * | 2014-12-22 | 2015-11-25 | 辽宁中医药大学 | 一种新骨架生物碱化合物及其提取分离方法 |
CN105085534B (zh) * | 2014-12-22 | 2017-11-10 | 辽宁中医药大学 | 一种生物碱化合物及其提取分离方法 |
CN111494567A (zh) * | 2020-05-27 | 2020-08-07 | 巧济堂(山东)药业有限公司 | 一种中药组合物及其制备方法、口服药剂、应用 |
CN114805175A (zh) * | 2022-05-24 | 2022-07-29 | 辽宁大学 | 马齿苋中新的化合物及其衍生物及其在治疗糖尿病药物中的应用 |
Also Published As
Publication number | Publication date |
---|---|
CN103110655B (zh) | 2015-03-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103110655B (zh) | 马齿苋生物碱单体化合物在制备抗肿瘤药物中的应用 | |
CN103316096A (zh) | 一种黑种草子总黄酮提取物及其制备方法和用途 | |
CN108640968B (zh) | 一种混源萜类化合物及其在制备抗炎药物中的用途 | |
CN101824067A (zh) | 玉蕊醇型三萜皂苷类化合物、制备方法及其应用 | |
CN101642450B (zh) | 二咖啡酰奎宁酸的制药用途 | |
CN102319291B (zh) | 一种构树叶总酚酸提取物及其在制备抗癌药物中的应用 | |
CN103830214A (zh) | 马齿苋生物碱单体化合物在制备抗肿瘤药物中的应用 | |
CN101890084A (zh) | 黑种草子总苷提取物及其制备方法和应用 | |
CN112898357B (zh) | 金莲花中一种二萜苷类新化合物及其分离纯化方法和应用 | |
CN101966172B (zh) | 咖啡酸及其衍生物的新用途 | |
CN102786562B (zh) | 一种吡咯里西啶生物碱及其用途 | |
CN100381434C (zh) | 具有抗癌、抗菌作用的余甘子提取物的中药制剂的生产方法 | |
CN101966194B (zh) | 野黄芩苷及其衍生物的新用途 | |
CN103610682B (zh) | 3α-羟基-30-齐墩果-12,20(29)-二烯-28-酸的制备方法和在制备抗肿瘤药物中的应用 | |
CN115521245A (zh) | 马齿苋中一种生物碱类化合物及其提取分离方法与应用 | |
CN105079011A (zh) | 一种具有抗肿瘤作用的药物的制备和应用 | |
CN102600191B (zh) | 青葙皂苷类化合物在制备抗肿瘤或抗炎药物中的应用 | |
CN102178725A (zh) | 黄花草木犀总皂苷及其制备方法和药物用途 | |
CN107722087B (zh) | 一种绞股蓝黄酮类化合物及其制备与在抗肿瘤药物中的应用 | |
CN101380356B (zh) | 藏药独一味总黄酮提取物及其提取方法和用途 | |
CN106588948B (zh) | 含氧桥环烯醚萜类化合物及其制备方法和用途 | |
CN103417528B (zh) | 一种异巴西红厚壳素的用途 | |
CN105640933A (zh) | 黄酮类化合物在制备抗乙肝病毒药物中的用途 | |
CN103214370B (zh) | 1,6-o-二咖啡酰山梨醇酯及其衍生物、和用途 | |
CN103553888B (zh) | 厚朴酚衍生物及其制备方法和在制备抗肿瘤药物中的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right |
Effective date of registration: 20190424 Address after: 110016 No. 83, cultural road, Shenhe District, Shenyang, Liaoning Patentee after: General Hospital of the Northern War Zone of the Chinese People's Liberation Army Address before: 110 840 No. 83 Cultural Road, Shenhe District, Shenyang City, Liaoning Province Patentee before: Zhao Qingchun |
|
TR01 | Transfer of patent right |